HeartBeam Granted Patent for Signal Transformation from Vector Electrocardiogram (VECG) to 12-Lead Electrocardiogram (ECG)
September 28 2022 - 8:31AM
Business Wire
Patented Technology Allows HeartBeam AIMIGo™
Credit Card-sized Device to Enable a 12-lead ECG Anytime,
Anywhere
HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology
company that has developed the first and only 3D-vector ECG
platform for heart attack detection anytime, anywhere, announced
today that its patent that enables generation of a synthesized
12-lead ECG by the HeartBeam AIMIGo™ credit card-sized device was
issued by the United States Patent and Trademark Office. The
innovation opens the pathway for a patient to record a set of
signals using HeartBeam AIMIGo outside of a medical setting with a
diagnostic synthesized 12-lead ECG immediately transmitted to a
physician for review and diagnosis. Unlike single-lead ECG products
currently in the marketplace, such as other credit card sized
devices or smartwatches, the HeartBeam technology is intended to
quickly and accurately help a physician identify a heart attack
(myocardial infarction).
In the US, approximately 18 million individuals have coronary
artery disease putting them at an increased risk for a heart attack
and making them ideal candidates for remote patient heart attack
detection. In contrast, the market for atrial fibrillation, the
most targeted condition for detection by single-lead ECG
technologies, is several times smaller. A 12-lead ECG is the
standard of care for detecting any cardiac condition and is
considered one of the essential tools for heart attack detection.
No single lead ECG product currently in the marketplace is able to
help diagnose a heart attack. HeartBeam’s technology will be the
first and only 12-lead ECG solution that fits in a consumer’s
wallet for use anytime, anywhere.
“This patent provides additional intellectual property
protection for our breakthrough AIMIGo technology offering 12-lead
ECG capability in the form of a credit card-sized device with the
same footprint as the single-lead products currently in the market
today,” said HeartBeam CEO and Founder Branislav Vajdic, PhD. “Our
12-lead AIMIGo technology, which is part of our granted patent,
offers the potential to bring a level of diagnostic accuracy
consistent with the current 12-lead ECG standard of care. This
could reduce the critical time to intervention for heart attack
patients, saving lives and reducing healthcare costs by ruling out
a heart attack and reducing the number of emergency room
visits.”
The newly issued patent (No. 11,445,963 B2) expands on
HeartBeam’s granted and pending core patents for remote heart
attack detection. The value of the recently granted 12-lead ECG
patch patent is in addressing the market need for multi-week,
continuous monitoring while the AIMIGo solution is always with the
patient, providing a means for timely heart attack intervention.
This may increase quality of life for cardiac patients by reducing
the fear of chest pain and provide added peace of mind. At the core
of both products is HeartBeam’s breakthrough ability to provide a
patient-friendly means of obtaining a 12-lead ECG anytime,
anywhere.
“The availability of a remote 12-lead ECG transmitted to a
physician while the patient is symptomatic and outside of a medical
facility allows a standard of care level of diagnostic work in any
setting and may potentially accelerate pre-hospital care,” said C.
Michael Gibson, MD, MS, CEO of the non-profit Baim and PERFUSE
research institutes at Harvard Medical School, also a leading
digital influencer, and Chairman of HeartBeam's Scientific Advisory
Board. “A 12-lead symptomatic signal combined with a 12-lead
baseline signal would provide additional information to aid in
diagnosing conditions such as myocardial infarction or more complex
arrhythmias that current single-lead remote cardiac technologies
cannot accurately detect.”
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a cardiac technology company
that has developed the first and only 3D-vector ECG platform for
heart attack detection anytime, anywhere. By applying a suite of
proprietary algorithms to simplify vector electrocardiography
(VECG), the HeartBeam platform enables patients and their
clinicians to determine if symptoms are due to a heart attack,
quickly and easily, so care can be expedited, if required.
HeartBeam has two patented products in development. HeartBeam AIMI™
is software for acute care settings that provides a 3D comparison
of baseline and symptomatic 12-lead ECG to more accurately identify
a heart attack. HeartBeam AIMIGo™ is the first and only credit
card-sized 12-lead output ECG device coupled with a smart phone app
and cloud-based diagnostic software system to facilitate remote
heart attack detection. HeartBeam AIMI and AIMIGo have not yet been
cleared by the US Food and Drug Administration (FDA) for marketing
in the USA or other geographies. For more information, visit
HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical
fact are "forward-looking statements." While management has based
any forward-looking statements included in this release on its
current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent
risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements, as a
result of various factors including those risks and uncertainties
described in the Risk Factors and in Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of our in our Forms 10-K, 10-Q and other reports filed with the SEC
and available at www.sec.gov. We urge you to consider those risks
and uncertainties in evaluating our forward-looking statements. We
caution readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
Except as otherwise required by the federal securities laws, we
disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained
herein (or elsewhere) to reflect any change in our expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220928005074/en/
Investor Relations Contact: Chris Tyson Executive Vice
President MZ North America Direct: 949-491-8235 BEAT@mzgroup.us
www.mzgroup.us
Media Contact:Capwell Communications
media@capwellcomm.com 949-999-3303
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Mar 2024 to Apr 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Apr 2023 to Apr 2024